Search

Your search keyword '"Turesson, Ingemar"' showing total 177 results
Start Over Author "Turesson, Ingemar" Search Limiters Peer Reviewed
177 results on '"Turesson, Ingemar"'

2. Germline variants at SOHLH2 influence multiple myeloma risk

Author

Duran-Lozano, Laura, Thorleifsson, Gudmar, Lopez de Lapuente Portilla, Aitzkoa, Niroula, Abhishek, Went, Molly, Thodberg, Malte, Pertesi, Maroulio, Ajore, Ram, Cafaro, Caterina, Olason, Pall I., Stefansdottir, Lilja, Bragi Walters, G., Halldorsson, Gisli H., Turesson, Ingemar, Kaiser, Martin F., Weinhold, Niels, Abildgaard, Niels, Andersen, Niels Frost, Mellqvist, Ulf-Henrik, Waage, Anders, Juul-Vangsted, Annette, Thorsteinsdottir, Unnur, Hansson, Markus, Houlston, Richard, Rafnar, Thorunn, Stefansson, Kari, and Nilsson, Björn

Published
2021
Full Text
View/download PDF

4. Direct evidence for a polygenic etiology in familial multiple myeloma

Author

Halvarsson, Britt-Marie, Wihlborg, Anna-Karin, Ali, Mina, Lemonakis, Konstantinos, Johnsson, Ellinor, Niroula, Abhishek, Cibulskis, Carrie, Weinhold, Niels, Försti, Asta, Alici, Evren, Langer, Christian, Pfreundschuh, Michael, Goldschmidt, Hartmut, Mellqvist, Ulf-Henrik, Turesson, Ingemar, Waage, Anders, Hemminki, Kari, Golub, Todd, Nahi, Hareth, Gullberg, Urban, Hansson, Markus, and Nilsson, Björn

Published
2017
Full Text
View/download PDF

7. Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma.

Author

Abildgaard, Niels, Freilich, Jonatan, Anttila, Pekka, Bent-Ennakhil, Nawal, Ma, Yuanjun, Lassenius, Mariann, Ørstavik, Sigurd, Toppila, Iiro, Waage, Anders, Turesson, Ingemar, and Hansson, Markus

Subjects
BORTEZOMIB, CANCER case studies, MULTIPLE myeloma, BONE marrow cancer, MEDICAL registries, LANGUAGE policy
Abstract

Purpose: Linked health-care registries and high coverage in Nordic countries lend themselves well to epidemiologic research. Given its relatively high incidence in Western Europe, complexity in diagnosis, and challenges in registration, multiple myeloma (MM) was selected to compare registries in Denmark, Finland, and Sweden.Patients and Methods: Data were obtained from four archetypal registries in each country (spanning January 2005–October 2018): National Patient Registry (NPR), Prescribed Drug Registry (PDR), Cancer Registry (CR), and Cause of Death Registry. Patients newly diagnosed with MM who received MM-specific treatment were included. PDR/NPR treatment records were used to assess incident NPR cases. The registration quality of MM-specific drugs in the PDR of each country was also evaluated.Results: In Denmark, only 6% of patients in the NPR were not registered in the CR; in Sweden, it was 16.9%. No systematic differences were identified that could explain this discrepancy. In Denmark, lenalidomide and bortezomib were registered in the NPR with high coverage, but less expensive drugs typically given in combination with bortezomib were not covered in any of the registries. In Finland and Sweden, bortezomib records were not identified in the PDR, but some were in the NPR; other drugs had good coverage in the PDR.Conclusions: The registries evaluated in this study can be used to identify the MM population; however, given the gaps in MM registration in the Finnish and Swedish CRs, Danish registries provide the most comprehensive datasets for research on treatment patterns for MM.Plain Language Summary: National patient registries collect observational data on populations of patients and are often used for research. In this study, we investigated how complete the national patient registries were for Denmark, Finland and Sweden when recording the number of patients with multiple myeloma (MM; a type of bone marrow cancer) between 2005 and 2018. We also investigated the completeness in registration of given treatments during the study period in the national registries. Overall, the Danish national patient registries had the most comprehensive information on patients with MM. Registry data from Denmark could therefore be useful for conducting further research into the characteristics, treatment patterns, and outcomes of patients with MM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, Molly, Sud, Amit, Försti, Asta, Halvarsson, Britt-Marie, Weinhold, Niels, Kimber, Scott, van Duin, Mark, Thorleifsson, Gudmar, Holroyd, Amy, Johnson, David C., Li, Ni, Orlando, Giulia, Law, Philip J., Ali, Mina, Chen, Bowang, Mitchell, Jonathan S., Gudbjartsson, Daniel F., Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Campo, Chiara, Bandapalli, Obul R, Einsele, Hermann, Gregory, Walter A., Gullberg, Urban, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Johnsson, Ellinor, Kristinsson, Sigurður Y., Mellqvist, Ulf-Henrik, Nahi, Hareth, Easton, Douglas, Pharoah, Paul, Dunning, Alison, Peto, Julian, Canzian, Federico, Swerdlow, Anthony, Eeles, Rosalind A., Kote-Jarai, ZSofia, Muir, Kenneth, Pashayan, Nora, Nickel, Jolanta, Nöthen, Markus M., Rafnar, Thorunn, Ross, Fiona M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Andersen, Niels Frost, Waage, Anders, Walker, Brian A., Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E., Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Goldschmidt, Hartmut, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Houlston, Richard S., and The PRACTICAL consortium

Published
2018
Full Text
View/download PDF

10. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Author

Mellqvist, Ulf-Henrik, Gimsing, Peter, Hjertner, Oyvind, Lenhoff, Stig, Laane, Edward, Remes, Kari, Steingrimsdottir, Hlif, Abildgaard, Niels, Ahlberg, Lucia, Blimark, Cecilie, Dahl, Inger Marie, Forsberg, Karin, Gedde-Dahl, Tobias, Gregersen, Henrik, Gruber, Astrid, Guldbrandsen, Nina, Haukås, Einar, Carlson, Kristina, Kvam, Ann Kristin, Nahi, Hareth, Lindås, Roald, Andersen, Niels Frost, Turesson, Ingemar, Waage, Anders, and Westin, Jan

Published
2013
Full Text
View/download PDF

15. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Author

Fayers, Peter M., Palumbo, Antonio, Hulin, Cyrille, Waage, Anders, Wijermans, Pierre, Beksaç, Meral, Bringhen, Sara, Mary, Jean-Yves, Gimsing, Peter, Termorshuizen, Fabian, Haznedar, Rauf, Caravita, Tommaso, Moreau, Philippe, Turesson, Ingemar, Musto, Pellegrino, Benboubker, Lotfi, Schaafsma, Martijn, Sonneveld, Pieter, and Facon, Thierry

Published
2011
Full Text
View/download PDF

17. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Author

Waage, Anders, Gimsing, Peter, Fayers, Peter, Abildgaard, Niels, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Dahl, Inger Marie, Forsberg, Karin, Gulbrandsen, Nina, Haukås, Einar, Hjertner, Øyvind, Hjorth, Martin, Karlsson, Torbjörn, Knudsen, Lene Meldgaard, Nielsen, Johan Lanng, Linder, Olle, Mellqvist, Ulf-Henrik, Nesthus, Ingerid, Rolke, Jürgen, Strandberg, Maria, Sørbø, Jon Hjalmar, Wisløff, Finn, Juliusson, Gunnar, and Turesson, Ingemar

Published
2010
Full Text
View/download PDF

19. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Author

Gimsing, Peter, Carlson, Kristina, Turesson, Ingemar, Fayers, Peter, Waage, Anders, Vangsted, Annette, Mylin, Anne, Gluud, Christian, Juliusson, Gunnar, Gregersen, Henrik, Hjorth-Hansen, Henrik, Nesthus, Ingerid, Dahl, Inger Marie S, Westin, Jan, Nielsen, Johan Lanng, Knudsen, Lene Meldgaard, Ahlberg, Lucia, Hjorth, Martin, Abildgaard, Niels, Andersen, Niels Frost, Linder, Olle, and Wisløff, Finn

Published
2010
Full Text
View/download PDF

27. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Author

Ludwig, Heinz, Durie, Brian G.M., Bolejack, Vanessa, Turesson, Ingemar, Kyle, Robert A., Blade, Joan, Fonseca, Rafael, Dimopoulos, Meletios, Shimizu, Kazuyuki, San Miguel, Jesus, Westin, Jan, Harousseau, Jean-Luc, Beksac, Meral, Boccadoro, Mario, Palumbo, Antonio, Barlogie, Bart, Shustik, Chaim, Cavo, Michele, Greipp, Philip R., Joshua, Douglas, Attal, Michel, Sonneveld, Pieter, and Crowley, John

Published
2008
Full Text
View/download PDF

34. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.

Author

Blimark, Cecilie Hveding, Vangsted, Annette Juul, Klausen, Tobias W., Gregersen, Henrik, Szabo, Agoston Gyula, Hermansen, Emil, Wålinder, Göran, Knut‐Bojanowska, Dorota, Zang, Chenyang, and Turesson, Ingemar

Subjects
MULTIPLE myeloma, CLINICAL trials, OVERALL survival, TREATMENT effectiveness
Abstract

Objective: We describe real‐world evidence (RWE) from the nationwide Swedish and Danish registries that provide important information on incidence and outcome in multiple myeloma (MM). Method: First line treatment data on more than 10.000 MM patients from Denmark and Sweden between 2005–2018 are presented. Key results from research conducted within the Swedish and Danish myeloma registries are summarized, describing subgroups of patients with comorbidity, myeloma complications, and early relapse. Results: We show that national guidelines, generated on results from randomized clinical trials (RCTs) are rapidly implemented and improve overall survival (OS). We find that both the incidence of MM and the median age at diagnosis is higher in national registries compared to results from referral centres, indicating a more complete coverage. This highlights the need of validation of prognostic scoring systems and indices in e.g., SMM and high‐risk MM in a real‐ world‐population. We show that these subgroups are unlikely to be captured in RCTs with narrow inclusion and exclusion criteria, that they have worse survival, and are in need of new treatment approaches. Conclusion: National registries that include all MM patients are an important source of knowledge on epidemiology, treatment and outcome with implications for the planning of MM care. Despite the introduction of new and better treatments, rapidly implemented in our countries, our registries uncover subgroups of patients that still have inferior outcome. Our RWE can help to identify important research questions to be studied in further clinical trials also in patients currently not included in RCTs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. International Staging System for Multiple Myeloma

Author

Greipp, Philip R., Miguel, Jesus San, Durie, Brian G.M., Crowley, John J., Barlogie, Bart, Bladé, Joan, Boccadoro, Mario, Child, J Anthony, Avet-Loiseau, Hervé, Kyle, Robert A., Lahuerta, Juan J., Ludwig, Heinz, Morgan, Gareth, Powles, Raymond, Shimizu, Kazuyuki, Shustik, Chaim, Sonneveld, Pieter, Tosi, Patrizia, Turesson, Ingemar, and Westin, Jan

Published
2005
Full Text
View/download PDF

44. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia

Author

Hallböök, Helene, Simonsson, Bengt, Ahlgren, Thomas, Björkholm, Magnus, Carneskog, Jan, Grimfors, Gunnar, Hast, Robert, Karlsson, Karin, Kimby, Eva, Lerner, Richard, Linder, Olle, Linderholm, Mats, Löfvenberg, Eva, Malm, Claes, Nilsson, Per-Gunnar, Paul, Christer, Stenke, Leif, Stockelberg, Dick, Tidefelt, Ulf, Turesson, Ingemar, Uden-Blome, Ann-Marie, Vilen, Lars, Wahlin, Anders, Winquist, Ingemar, and Smedmyr, Bengt

Published
2002
Full Text
View/download PDF

47. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.

Author

Jonsdottir, Gudbjorg, Björkholm, Magnus, Turesson, Ingemar, Hultcrantz, Malin, Diamond, Benjamin, Porwit, Anna, Landgren, Ola, and Kristinsson, Sigurdur Y.

Subjects
MULTIPLE myeloma, ACUTE myeloid leukemia, MYELODYSPLASTIC syndromes, MELPHALAN, DIAGNOSIS
Abstract

Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). Methods: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to December 31, 2011. A total of 26 627 patients were diagnosed with MM with during the study period. Of these, 124 patients (0.5%) developed subsequent AML/MDS. For each patient with MM and a subsequent AML/MDS diagnosis, we randomly selected a matched (age, sex, and date of MM diagnosis) MM patient without a subsequent second malignancy diagnosis. Results: The cumulative melphalan exposure was significantly higher (OR = 2.8, 95% CI 1.7‐5.2; P <.001) among cases (median 988 mg; IQR 644‐1640) compared with controls (median 578 mg; IQR 360‐967). Median time to AML/MDS development was 3.8 years (IQR 2.8‐5.8). Risk of AML/MDS was not statistically altered by M protein isotype, anemia, renal failure, hypercalcemia, lytic bone lesions, or radiation therapy. Conclusion: In this nationwide population‐based study, we show that increased cumulative doses of alkylating therapy with melphalan increases the subsequent risk of developing AML/MDS in patients with MM. Given improved survival in MM patients over the last decade future studies will be important to better define long‐term risks. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results